Researcher:
Mutluer, Ferit Onur

Profile Picture
ORCID

Job Title

Doctor

First Name

Ferit Onur

Last Name

Mutluer

Name

Name Variants

Mutluer, Ferit Onur

Email Address

Birth Date

Filters

2017 - 2019232020 - 20213

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.e2132452-27ca-4fea-a3e2-41616a2a0f9a

Search Results

Now showing 1 - 10 of 26
  • Placeholder
    PublicationMetadata only
    Author`s reply
    (CardioFront LLC, 2018) Aksu, Tolga; Güler, Tümer Erdem; N/A; Mutluer, Ferit Onur; Faculty Member; School of Medicine; Koc University Hospital; N/A
    N/A
  • Placeholder
    PublicationMetadata only
    Long-term outcomes of catheter ablation of ventricular tachycardia in patients with ischemic cardiomyopathy
    (Kocaeli Derince Training and Research Hospital, 2019) Kanat, Selçuk; N/A; Mutluer, Ferit Onur; Faculty Member; School of Medicine; N/A
    INTRODUCTION: For ablation of ventricular tachycardia (VT) in patients with ischemic cardiomyopathy (ICM), an electroanatomical mapping (3D EAM) system is constantly used. The goal of this study was to determine the long-term outcomes of substrate mapping and catheter ablation (CA) of Ventricular Tachycardia in ICM. METHODS: The study included 41 consecutive patients with ICM. Substrate mapping and ablation were performed to all patients using 3D EAM. Patients were followed up for acute procedure success, periprosedural complications, mortality and recurrence of VT. RESULTS: For patients that included in this study, mean age was 61 ± 7 and majority of the patients was male (38, 92.6 %). Mean follow-up duration was 16.5 ± 8.5 months and in the follow up duration 6 (14,6%) of study patients were lost and 10 (24,3%) experienced VT recurred. Periprocedural complications occurred in 5 of the patients (11.9 %). DISCUSSION and CONCLUSION: In a single center retrospective study, when using a 3D EAM guided approach for VT ablation in patients with ischemic cardiomyopathy, the freedom from any ventricular arrhythmia has found high (75.6 %). Substrate mapping and ablation during on sinus rhythm or under pacing shown as successful which we demonstrated in our study. / GİRİŞ ve AMAÇ: İskemik kardiyomiyopatili (ICM) hastalarda ventriküler taşikardinin (VT) ablasyonu için sürekli olarak bir elektroanatomik haritalama (3D EAM) sistemi kullanılmaktadır. Bu çalışmanın amacı, ICM'de ventriküler taşikardide substrat haritalama ve kateter ablasyonunun (CA) uzun dönem sonuçlarını belirlemektir. YÖNTEM ve GEREÇLER: Çalışmaya ICM'li 41 ardışık hasta alındı. 3D EAM kullanan tüm hastalara substrat haritalama ve ablasyon uygulandı. Hastalar akut işlem başarısı, periprosedural komplikasyonlar, mortalite ve VT nüksü açısından takip edildi. BULGULAR: Bu çalışmaya dahil edilen hastalar için yaş ortalaması 61 ± 7 ve hastaların çoğu erkekti (38% 92,6). Ortalama takip süresi 16,5 ± 8,5 aydı ve takip süresinde 6 (% 14,6) hasta kaybedildi ve 10 (% 24,3) VT olgusunda nüks görüldü. Periprosedural komplikasyonlar hastaların 5'inde (% 11.9) meydana geldi. TARTIŞMA ve SONUÇ: Tek merkezli bir retrospektif çalışmada, iskemik kardiyomiyopatili hastalarda için,3D EAM destekli bir yaklaşım ile VT ablasyonu uygulandığında,uzun dönem başarısı yüksek bulundu (% 75.6). Çalışmamızda, sinüs ritmi yada ventriküler pacing altında, substrat haritalama ve ablasyon başarısı gösterilmiştir.
  • Placeholder
    PublicationMetadata only
    A practical and case-based approach to thrombocytopenia in cardiology practice
    (Turkish Soc Cardiology, 2018) N/A; N/A; Öztürk, Erman; Mutluer, Ferit Onur; Doctor; Faculty Member; School of Medicine; N/A; Koç University Hospital; N/A; N/A; N/A
    In cardiology practice, anticoagulation and antiplatelet therapies are essential for most patients. As of yet, there is no high quality evidence regarding these treatments in thrombocytopenic patients, which continues to be an issue. Thrombocytopenia is defined as a platelet count of <150x10(9)/L and is classified as severe when the platelet count is <50x10(9)/L. Pseudothrombocytopenia, drug-induced thrombocytopenia, immune thrombocytopenia, heparin-induced thrombocytopenia, and thrombotic thrombocytopenic purpura are some of the main causes of thrombocytopenia. The current treatment suggestions are conservative, as a result of the lack of evidence, built on defensive treatment strategies and the fear of bleeding complications. Many patients with acute myocardial infarction with thrombocytopenia have undergone percutaneous coronary intervention successfully with adjunctive antiplatelet and anticoagulant use, as has been described in case reports. A risk-benefit ratio should be evaluated for antiplatelet therapy. In the relevant guidelines, while full dose low-molecular-weight heparin (LMWH) is recommended for patients with a thrombocyte count of >50x10(9)/L, a half-dose of LMWH is recommended in patients with thrombocytopenia between 25 and 50x10(9)/L. According to the current guidelines, avoiding antiplatelet and anticoagulant treatment should be restricted to patients with very severe thrombocytopenia (i.e., a platelet count <25x10(9)/L), but new data and recommendations are needed.
  • Placeholder
    PublicationMetadata only
    Interleukin-1 gene cluster polymorphisms associated with coronary slow flow phenomenon reply
    (Turkish Soc Cardiology, 2018) Güngör, Barış; Bolca, Osman; Aksu, Tolga; N/A; Mutluer, Ferit Onur; Ural, Dilek; Doctor; Faculty Member; N/A; School of Medicine; Koç University Hospital; N/A; N/A; 1057
    N/A
  • Placeholder
    PublicationMetadata only
    Interleukin-1 gene cluster polymorphisms associated with coronary slow flow phenomenon ( Author`s Reply )
    (Kare Publishing, 2018) Güngör, Barış; Bolca, Osman; Aksu, Tolga; N/A; Mutluer, Ferit Onur; Ural, Dilek; Doctor; Faculty Member; N/A; School of Medicine; Koç University Hospital; N/A; 1057
    N/A
  • Placeholder
    PublicationMetadata only
    Increased exercise-related platelet activation assessed by impedance aggregometry in diabetic patients despite aspirin therapy
    (Springer, 2019) Cakir, Hakan; Kaymaz, Cihangir; Tanboga, Ibrahim Halil; Cakir, Hilal; Tokgoz, Hacer Ceren; Hakgor, Aykun; Akbal, Ozgur Yasar; Er, Fahri; Topal, Dursun Demir, Mehmet; Tenekecioglu, Erhan; N/A; Mutluer, Ferit Onur; Faculty Member; School of Medicine; N/A
    Aspirin is widely used for the prevention of thromboembolic diseases, but inhibition of platelet aggregation (PA) is not uniform. Additionally, aspirin has been shown to be ineffective in blunting PA in response to exercise in patients with coronary artery disease (CAD). Limited data exists about platelet function following acute exercise in diabetics taking aspirin. In our study, we aimed to investigate PA before and after exercise stress test in type-2 diabetic patients taking aspirin. Forty-three patients with type-2 diabetes mellitus (DM) and 36 subjects (age- and sex-matched) as control group were included prospectively. All participants were under aspirin (100mg/day) therapy for at least 1 week. The measures of PA were assessed by impedance aggregometry using arachidonic acid as an agonist(ASPI test). Blood samplings were undertaken before and immediately after treadmill exercise test. At rest, diabetic and control groups had comparable pre-exercise PA (22.97 +/- 14.57 versus 22.11 +/- 12.71 AUmin, p=NS, respectively). After treadmill exercise, both groups showed significantly higher absolute increase (9.02 +/- 13.08 and 3.66 +/- 5.87 AUmin, p<0.01, p<0.01, respectively) and percent (%) increase (45.67 +/- 49.34 and 24.04 +/- 46.59 AU min, p<0.01, p=0.01, respectively) in PA. Both absolute increase (p<0.05) and % increase (p<0.05) in PA were significantly higher in DM group compared to the control group. Multiple regression analysis revealed that high-sensitive C-reactive protein (p=0.014) was independent predictor of absolute increase PA. Our study showed that aspirin has limited effect in inhibiting exercise-induced PA, even in the absence of documented CAD. The increase in PA following exercise was significantly greater in patients with DM compared with controls.
  • Placeholder
    PublicationMetadata only
    The relationship between hemoglobin A1c levels and thrombus load in patients with type 2 diabetes mellitus and non-ST-segment elevation myocardial infarction
    (Wolters Kluwer Medknow Publications, 2021) Topal, Dursun; Aydin, Omur; Cakir, Hakan; Kanat, Selcuk; Aslan, Burhan; Er, Fahri; Uslu, Abdulkadir; Bozkaya, Veciha; Keskin, Muhammed; Karsi, Remzi; Yilmaz, Mustafa; Aksakal, Enbiya; Demir, Mehmet; Tenekecioglu, Erhan; N/A; Mutluer, Ferit Onur; Faculty Member; School of Medicine; Koc University Hospital; N/A
    Background: We aimed to investigate the relationship between hemoglobin A1c (HbA1c) and coronary thrombus load in type-2 diabetes mellitus (T2DM) patients with non-ST segment elevation myocardial infarction (NSTEMI). Materials and Methods: Ninety diabetic patients with NSTEMI were recruited for the study. They were separated into two groups according to HbA1c levels. Forty-seven patients having HbA1c ≤6.5% formed Group-I (35 male, mean age 58 ± 10.5 years) and the remaining 43 patients with HbA1c >6.5% formed Group-II (23 male, mean age 58 ± 11.1 years). Both the groups were evaluated in terms of thrombolysis in myocardial infarction (TIMI) thrombus score and Syntax score. Results: Baseline patient characteristics were comparable in both the groups. TIMI thrombus score and Syntax score were higher in Group II than in Group I (3.2 ± 1.4 vs. 4.7 ± 0.5 and 20.2 ± 3.4 vs. 26.3 ± 3.0 respectively, P < 0.05). No significant difference was found in other parameters. In stepwise linear regression analysis, prepercutaneous coronary intervention (PCI) and post-PCI TIMI frame number and HbA1c were significantly related to the coronary thrombus scale. However, no significant relationship has been found between thrombus formation and hypertension, previous PCI history, pre-PCI heart rate, pre-PCI cholesterol status, and high-sensitive troponin T. Conclusion: In NSTEMI with T2DM, increased HbA1c (HbA1c >6.5%) is related with coronary thrombus in the target vessel. In those patient population, strict anticoagulation should be considered to prevent potential adverse events. 2022 Royal Society of Chemistry. .
  • Placeholder
    PublicationMetadata only
    AMPLATZER Muscular Ventricular Septal Occluder in transcatheter occlusion of the left main coronary artery in a patient with a huge aneurysm secondary to Kawasaki disease
    (Europa Edition, 2019) Çeliker, Alpay; N/A; Mutluer, Ferit Onur; Yıldız, Ömer; Doctor; Doctor; N/A; School of Medicine; Koç University Hospital; Koç University Hospital; N/A; N/A
    N/A
  • Placeholder
    PublicationMetadata only
    The rationale and design of the national peripartum cardiomyopathy registries in Turkey: the Artemis-I and Artemis-II studies
    (Aves, 2018) Kayikcioglu, Meral; Tokgozoglu, Lale; Ural, Dilek; Biteker, Murat; N/A; Mutluer, Ferit Onur; Faculty Member; School of Medicine; N/A
    Objective: Peripartum cardiomyopathy (PPCM) is left ventricular (LV) systolic dysfunction with an ejection fraction of <= 45% occurring in the later stages of pregnancy or soon after delivery. Although various risk factors have been identified, the exact cause of the disease is unknown. Unlike most countries in the European region, Turkey has yet to determine the current PPCM burden. A registry for this purpose does not exist. To close this gap, the A RegisTry of pEripartuM cardIomyopathy in Turkish patientS (ARTEMIS-I and ARTEMIS-II), was planned and endorsed by the Turkish Society of Cardiology. The aim of this manuscript is to describe the rationale and design of the ARTEMIS-I and ARTEMIS-II registries. Methods: ARTEMIS was designed to be the nationwide PPCM registry of Turkey, with the goal of identifying problems and opportunities while improving quality and consistency in the medical care of PPCM patients. A second goal is to determine the clinical characteristics pertinent to patients in this region. The ARTEMIS registry will consist of 2 arms. All secondary and tertiary cardiology centers have been electronically invited to participate in ARTEMIS-I, which will be conducted to assess the current standard of care and outcome measures. Centers will be asked to enroll PPCM patients admitted to their clinic in last 5 years retrospectively. Eligibility criteria will consist of pregnant or early postpartum woman without a previous history of heart failure (HF) or known pathology associated with HF, LV ejection fraction <= 45%, and exclusion of other causes of LV systolic dysfunction. ARTEMIS-II will consist of the prospective enrollment of patients. Conclusion: The nationwide PPCM registries, ARTEMIS-I and ARTEMIS-II, are designed to determine the current status of medical care, provide insights into nature of the disease, and suggest solutions on how to improve care and outcomes in these patients.
  • Placeholder
    PublicationMetadata only
    General concepts in adult congenital heart disease
    (Galenos Yayınevi, 2018) Celiker, Alpay; N/A; Mutluer, Ferit Onur; Faculty Member; School of Medicine; Koç University Hospital; N/A
    Congenital heart disease in adults (adult congenital heart disease) is a growing burden for healthcare systems. While infant mortality due to congenital heart disease in the last four decades decreased by almost 3-fold, adult congenital heart disease prevalence increased by more than 2-fold in United States. Adult congenital heart disease prevalence is expected to increase steadily until 2050 in projections. Adult congenital heart disease is a multifaceted problem with many dimensions. This manuscript aims to provide an overview of the common adult congenital heart diseases and summarize important points in management of these diseases with possible problems and complications that the patients and the physicians face.